UBT251

GLP-1 + GIP + glucagon triple agonist · Novo Nordisk

Top dose

6 mg

Weight loss

-19.7%

at week 24 · treatment regimen

AE discontinuation

4.0%

Status

phase 2

Pivotal trial #

Trial: Ph 2 China (n=205)
Indication: obesity
Duration: 24 weeks
Sponsor: Novo Nordisk

Notes #

Licensed by Novo from United Biotech (China) in Mar 2025, ex-Greater China rights. Ph2 China 24-wk readout: 6 mg = -19.7% vs placebo -2.0% (baseline 92.2 kg). >=20% WL: 48.4% at 6 mg vs 0% placebo. TEAEs 88-92%; AE-led disc 0-4% across UBT251 arms - notably low for a triple. Headline at 24 wks is still on titration curve (shorter than STEP/REDEFINE/TRIUMPH); upside if WL continues. Global Ph1b/2a (28-wk, 5-arm) ongoing; obesity readout H1 2027. Source: Novo R&D Day 2026 + 24 Feb / 25 Mar 2026 PRs.